ENDRA Life Sciences Inc. — Director's Dealing 2017

May 16, 2017

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: ENDRA Life Sciences Inc. (NDRA)
CIK: 0001681682
Period of Report: 2017-05-08

Reporting Person: Thornton Michael Milos (Chief Technology Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	4967	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Options	$10.01	2018-11-01	Common Stock (29470)		Direct
Warrants to Purchase Common Stock	$20.02	2021-01-19	Common Stock (999)		Direct
Convertible Promissory Note	$1.40	2017-05-12	Common Stock ()		Direct

Footnotes

F1: Stock Options with respect to 3,462 shares of Common Stock became exercisable on November 1, 2013 and Stock Options with respect to 22,008 shares of Common Stock became exercisable in three equal annual installments beginning on November 13, 2013.

F2: The principal amount of, and accrued interest on, the Convertible Promissory Note is convertible into shares of Common Stock of the Issuer at a
conversion price of $1.40 per share immediately prior to the consummation of the Issuer's initial public offering.